Self assembly Biological molecules are important lines to understand the molecular basis of complex metabolic events. The presence of cosolvent in aqueous solution during the self-assembly process can promote the formation of a metasable intermediary that is trapped in Kina. In nature, cosolvents categories called osmolytes can work to strengthen hydrogen bond tissue in such a way that the original conditions of certain proteins are preferred, thus modulating their functions and stability. However, identifying COSOLVENTs that act as osmolytes in biomimetic applications, such as self-assignment of soft materials, remain challenging.
This work examines the effects of ethanol (ETOH) and acetonitrile (ACN) as cosolven at the self-assignment of Amphiphilic Polypeptide PSAR30- (L-LEU-AIB) 6 (S30L12), which combines α-helical hydrophobic blocks, in aqueous solution. The result gives direct observation of the morphological behavior of S30L12 as a function of solvent composition. Morfological transitions are investigated using electron microscope transmissions, while peptide molecular packaging is assessed using circular blocked analysis and evaluating membrane fluidity.
In the mixture of Etoh / H2O, EtOH strengthens the water hydrogen bond tissue, thus limiting the hydrophobic hydration of the S30L12 assembly and increasing hydrophobic interactions between assemblies. Conversely, ACN forms its own nanoclusters in water and on the hydrophobic core of peptide assemblies to stabilize the edges exposed to bulk water and increase assembly kinetics. Fourier Transform Infrared Analysis (FT-IR) shows that EtOH and ACN can modify biomaterial self assembly in the same way as protective or denaturant osmolyte.
Poisonous polypeptide production as fusion inside the recit cavity
This system was developed for efficient biosynthetic production of painsty polypeptides. A polipeptide target produced blends into the T. thermophilus tassel polpeptide in such a way that it is served in the purai cavity near the substrate binding surface. Such presentations allow the relieve potential issues instability, toxicity or peptide hydrophobicity that blends. Thermostilical thermostabilities can be used to separate a one-step from the host cell protein by heating. The target of polypeptides can be released by special chemical care amino acids.
In this study, Groel was adapted for special methionine cleavage with cyanogen bromide with a total metionine residue replacement to facilitate further purification of the polipeptide target. The procedure is simple, strong, and easy to improve. The capacity of this system to produce polypeptides that is difficult to express is shown by production in the bacterial system from one of the most powerful antibacterial peptides polyphemusin I.
Adenilaty Adenilaty Polypeptide Adenilaty Cyclase: Neuroprotective Peptides that Promise in Stroke
Searching for effective and effective care for acute strokes continues to be a global priority due to high mortality and morbidity. Terapeutic treatment currently has limited effects, making searches for imperative new care. Polypeptides in the pituitary clasp (Pacip) are established cytoprotective neuropeptide participating in various physiological and pathological activities of nerves, such as neuron proliferation, differentiation, and migration, and neuroprotection. This is considered a promising treatment in many neurological diseases.
Thus, PACAP bears potential as a new therapeutic strategy for stroke treatment. Here, we provide an overview that is related to the current PACAP knowledge, its receptors, and the potential role of neuroprotective in stroke settings, as well as various neuroprotecting mechanisms involving ion homeostasis, excitoxicity, cell edema, and oxidative stress ,, and cell death, and the route of giving Pacap.
Polypeptide Amyloid Islet & Beta Amyloid Peptide Role In Alzheimer’s Disease: Two Triggers, One Disease
Alzheimer’s disease (AD) is a neurodegenerative disorder that affects millions throughout the world. Because of the aging of the population, advertising events increase. Ad patients develop cognitive and dementia decreases, known features, requires permanent care. This raises the main socio-economic burden on the health care system because relatives and health workers are patients forced to overcome the increasing number of people affected. Despite the latest advances, the pathological mechanism of advertising is not fully understood.

However, it is clear that the amyloid beta (Aβ) peptide, which forms amyloid plaque in the brain of AD patients, plays a key role. Type 2 diabetes, the most common form of diabetes, affects hundreds of millions of people globally. The amyloid polypeptide (IAPP) islet is a hormone produced and released by insulin in the β-β pancreas, with a key role of diabetes, because it helps regulate glucose levels and control adiposity and pursuit. Likewise with Aβ, IAPP is very amyloidogenic, produces intracellular amyloid deposits that cause β cell dysfunction and death.
BCL3 Peptide |
7183P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (CT) BCL3 Peptide |
BCL-10 Peptide |
2161P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (NT) BCL-10 peptide |
Bcl-2 Peptide |
3335P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (NT) Bcl-2 peptide |
Bcl-2 Peptide |
3337P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (IN) Bcl-2 peptide |
Bcl9L Peptide |
6213P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (NT) Bcl9L peptide |
BCL7A Peptide |
45-325P |
ProSci |
0.1 mg |
EUR 405.6 |
Description: BCL7A Peptide |
BCL2A1 Peptide |
42-665P |
ProSci |
0.1 mg |
EUR 405.6 |
Description: (IN) BCL2A1 Peptide |
BCL2L15 Peptide |
43-245P |
ProSci |
0.1 mg |
EUR 405.6 |
BCL2L15 Peptide |
42-323P |
ProSci |
0.1 mg |
EUR 405.6 |
Description: (IN) BCL2L15 Peptide |
BCL10 Blocking Peptide |
DF6246-BP |
Affbiotech |
1mg |
EUR 234 |
BCL10 Blocking Peptide |
DF3606-BP |
Affbiotech |
1mg |
EUR 234 |
BCL11A Blocking Peptide |
AF7561-BP |
Affbiotech |
1mg |
EUR 234 |
BCL11A Blocking Peptide |
33R-10043 |
Fitzgerald |
100 ug |
EUR 216 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL11A antibody, catalog no. 70R-8372 |
BCL11A Blocking Peptide |
33R-6490 |
Fitzgerald |
100 ug |
EUR 216 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL11A antibody, catalog no. 70R-8336 |
BCL11A Blocking Peptide |
DF7345-BP |
Affbiotech |
1mg |
EUR 234 |
BCL11B Blocking Peptide |
DF2464-BP |
Affbiotech |
1mg |
EUR 234 |
BCL2 Blocking Peptide |
20-abx062289 |
Abbexa |
|
|
|
Bcl2 Blocking Peptide |
33R-10602 |
Fitzgerald |
50 ug |
EUR 229.2 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Bcl2 antibody, catalog no. 70R-11571 |
BCL3 Blocking Peptide |
33R-10746 |
Fitzgerald |
50 ug |
EUR 229.2 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL3 antibody, catalog no. 70R-11804 |
BCL9 Blocking Peptide |
DF12515-BP |
Affbiotech |
1mg |
EUR 234 |
BCL2 Blocking Peptide |
20-abx161300 |
Abbexa |
|
|
|
BCL2 Blocking Peptide |
20-abx161556 |
Abbexa |
|
|
|
BCL9L Blocking Peptide |
AF7915-BP |
Affbiotech |
1mg |
EUR 234 |
BCL7A Blocking Peptide |
33R-1704 |
Fitzgerald |
100 ug |
EUR 216 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL7A antibody, catalog no. 70R-3771 |
BCL6B Blocking Peptide |
33R-5338 |
Fitzgerald |
100 ug |
EUR 216 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL6B antibody, catalog no. 70R-8459 |
BCL7A Blocking Peptide |
33R-7534 |
Fitzgerald |
100 ug |
EUR 216 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL7A antibody, catalog no. 70R-3765 |
BCL6B Blocking Peptide |
DF9075-BP |
Affbiotech |
1mg |
EUR 234 |
BCL7A Blocking Peptide |
DF4737-BP |
Affbiotech |
1mg |
EUR 234 |
BCL7B Blocking Peptide |
DF2586-BP |
Affbiotech |
1mg |
EUR 234 |
BCL7C Blocking Peptide |
DF2587-BP |
Affbiotech |
1mg |
EUR 234 |
BCL2A1 Blocking Peptide |
33R-2930 |
Fitzgerald |
100 ug |
EUR 216 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL2A1 antibody, catalog no. 70R-10524 |
BCL2L1 Blocking Peptide |
33R-8657 |
Fitzgerald |
100 ug |
EUR 216 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL2L1 antibody, catalog no. 20R-1065 |
BCL2L1 Blocking Peptide |
33R-5547 |
Fitzgerald |
100 ug |
EUR 216 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL2L1 antibody, catalog no. 70R-10444 |
BCL2L1 Blocking Peptide |
33R-6481 |
Fitzgerald |
100 ug |
EUR 216 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL2L1 antibody, catalog no. 70R-10443 |
BCL2A1 Blocking Peptide |
DF7652-BP |
Affbiotech |
1mg |
EUR 234 |
BCL2L1 Blocking Peptide |
DF6015-BP |
Affbiotech |
1mg |
EUR 234 |
BCL2L2 Blocking Peptide |
DF6292-BP |
Affbiotech |
1mg |
EUR 234 |
BCL2L13 Blocking Peptide |
33R-9493 |
Fitzgerald |
100 ug |
EUR 216 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL2L13 antibody, catalog no. 70R-10451 |
BCL2L12 Blocking Peptide |
33R-4918 |
Fitzgerald |
100 ug |
EUR 216 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL2L12 antibody, catalog no. 70R-10366 |
BCL2L14 Blocking Peptide |
DF9220-BP |
Affbiotech |
1mg |
EUR 234 |
BCL2L12 Blocking Peptide |
DF3830-BP |
Affbiotech |
1mg |
EUR 234 |
BCL2L13 Blocking Peptide |
DF6248-BP |
Affbiotech |
1mg |
EUR 234 |
BCL2L10 Blocking Peptide |
DF2276-BP |
Affbiotech |
1mg |
EUR 234 |
BCL2L13 Blocking Peptide |
DF2649-BP |
Affbiotech |
1mg |
EUR 234 |
BCL-3 Blocking Peptide |
AF7756-BP |
Affbiotech |
1mg |
EUR 234 |
Bcl-2 Blocking Peptide |
3033BP-50 |
Biovision |
each |
EUR 183.6 |
Bcl-3 Blocking Peptide |
3407BP-50 |
Biovision |
each |
EUR 183.6 |
Bcl-6 Blocking Peptide |
3408BP-50 |
Biovision |
each |
EUR 183.6 |
Bcl-2 Blocking Peptide |
BF9103-BP |
Affbiotech |
1mg |
EUR 234 |
BCL-2 Blocking Peptide |
AF0769-BP |
Affbiotech |
1mg |
EUR 234 |
Bcl-2 Blocking Peptide |
AF4700-BP |
Affbiotech |
1mg |
EUR 234 |
BCL-2 Blocking Peptide |
AF6139-BP |
Affbiotech |
1mg |
EUR 234 |
BCL-3 Blocking Peptide |
DF10317-BP |
Affbiotech |
1mg |
EUR 234 |
BCLAF1 Peptide |
8373P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: BCLAF1 Peptide |
BCL2 (pT56) Blocking Peptide |
20-abx061740 |
Abbexa |
|
|
|
BCL2 (pS70) Blocking Peptide |
20-abx061755 |
Abbexa |
|
|
|
BCL2 (pS70) Blocking Peptide |
20-abx062038 |
Abbexa |
|
|
|
BCL2 (pT69) Blocking Peptide |
20-abx062288 |
Abbexa |
|
|
|
BCL2 (pS87) Blocking Peptide |
20-abx161301 |
Abbexa |
|
|
|
Bcl-B Peptide |
3163P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (IN) Bcl-B peptide |
Bcl-G Peptide |
3165P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (NT) Bcl-G peptide |
Bcl-xL Peptide |
3341P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (CT) Bcl-xL peptide |
Bad / Bcl-2-like 8 Peptide |
3343P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (CT) Bad / Bcl-2-like 8 peptide |
Bcl-rambo Peptide |
3023P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (IN) Bcl-rambo peptide |
BCLW Blocking Peptide |
20-abx062039 |
Abbexa |
|
|
|
BclB Blocking Peptide |
33R-10884 |
Fitzgerald |
50 ug |
EUR 229.2 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BclB antibody, catalog no. 70R-12009 |
BCLW Blocking Peptide |
DF3607-BP |
Affbiotech |
1mg |
EUR 234 |
BCLX Blocking Peptide |
20-abx161558 |
Abbexa |
|
|
|
bcl-2-related protein A1 Peptide |
43-369P |
ProSci |
0.1 mg |
EUR 405.6 |
BCLAF1 Blocking Peptide |
20-abx063617 |
Abbexa |
|
|
|
BCLAF1 Blocking Peptide |
DF3828-BP |
Affbiotech |
1mg |
EUR 234 |
Bcl xL Blocking Peptide |
33R-10466 |
Fitzgerald |
50 ug |
EUR 418.8 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Bcl xL antibody, catalog no. 20R-1516 |
Bcl 6 Blocking Peptide |
33R-10485 |
Fitzgerald |
50 ug |
EUR 418.8 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Bcl 6 antibody, catalog no. 20R-1556 |
Bcl-B Blocking Peptide |
3695BP-50 |
Biovision |
each |
EUR 183.6 |
BCL-XL Blocking Peptide |
AF6414-BP |
Affbiotech |
1mg |
EUR 234 |
BCL-XL Blocking Peptide |
AF6415-BP |
Affbiotech |
1mg |
EUR 234 |
Bcl-xL Blocking Peptide |
33R-10707 |
Fitzgerald |
50 ug |
EUR 229.2 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Bcl-xL antibody, catalog no. 70R-11750 |
Bcl-xL Blocking Peptide |
3312BP-50 |
Biovision |
each |
EUR 183.6 |
BCLX (pS62) Blocking Peptide |
20-abx161302 |
Abbexa |
|
|
|
BCLX (pT47) Blocking Peptide |
20-abx161557 |
Abbexa |
|
|
|
Bcl-Rambo Blocking Peptide |
3671BP-50 |
Biovision |
each |
EUR 183.6 |
TKD Peptide (Hsp70 Peptide) (Hsp70 Peptide) |
SIH-118A |
Stressmarq |
1 mg |
EUR 374.4 |
|
Description: The substance TKD Peptide (Hsp70 Peptide) is a hsp70 peptide. It is synthetically produced and has a purity of >98%. The pure substance is solid which is In aqueous solution. |
TKD Peptide (Hsp70 Peptide): FITC (Hsp70 Peptide) |
SIH-119A |
Stressmarq |
1 mg |
EUR 430.8 |
|
Description: The substance TKD Peptide (Hsp70 Peptide): FITC is a hsp70 peptide. It is synthetically produced and has a purity of >98%. The pure substance is solid which is In aqueous solution. |
TKD Peptide (Hsp70 Peptide) |
abx076809-1mg |
Abbexa |
1 mg |
EUR 594 |
|
Rat Peptide YY (PYY) Peptide |
20-abx068453 |
Abbexa |
-
EUR 744.00
-
EUR 326.40
-
EUR 2230.80
-
EUR 878.40
-
EUR 543.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Connecting Peptide (C-Peptide) Peptide |
abx670072-05mg |
Abbexa |
0.5 mg |
EUR 678 |
|
Human Peptide YY (PYY) Peptide |
20-abx068451 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2013.60
-
EUR 811.20
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Mouse Peptide YY (PYY) Peptide |
20-abx068452 |
Abbexa |
-
EUR 710.40
-
EUR 309.60
-
EUR 2131.20
-
EUR 844.80
-
EUR 526.80
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
TKD Peptide (Hsp70 Peptide) (FITC) |
abx076810-1mg |
Abbexa |
1 mg |
EUR 678 |
|
Rat Connecting Peptide (C-Peptide) Peptide (OVA) |
20-abx651058 |
Abbexa |
-
EUR 510.00
-
EUR 276.00
-
EUR 1378.80
-
EUR 594.00
-
EUR 376.80
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
BCL6 siRNA |
20-abx908994 |
Abbexa |
|
|
|
BCL6 siRNA |
20-abx908995 |
Abbexa |
|
|
|
Dog Peptide YY (PYY) Peptide (OVA) |
20-abx651198 |
Abbexa |
-
EUR 427.20
-
EUR 260.40
-
EUR 1178.40
-
EUR 526.80
-
EUR 343.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Pig Peptide YY (PYY) Peptide (OVA) |
20-abx651200 |
Abbexa |
-
EUR 427.20
-
EUR 260.40
-
EUR 1178.40
-
EUR 526.80
-
EUR 343.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Rat Peptide YY (PYY) Peptide (OVA) |
20-abx651201 |
Abbexa |
-
EUR 427.20
-
EUR 260.40
-
EUR 1178.40
-
EUR 526.80
-
EUR 343.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
BCL6 antibody |
10R-1574 |
Fitzgerald |
100 ug |
EUR 614.4 |
Description: Mouse monoclonal BCL6 antibody |
BCL6 Antibody |
25523-100ul |
SAB |
100ul |
EUR 468 |
BCL6 Antibody |
37150-100ul |
SAB |
100ul |
EUR 302.4 |
BCL6 antibody |
70R-11805 |
Fitzgerald |
100 ug |
EUR 552 |
Description: Rabbit polyclonal BCL6 antibody |
BCL6 Antibody |
6985-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: BCL6 Antibody: BCL6 was first identified as a proto-oncogene in diffuse large B cell lymphoma. BCL6, a transcriptional repressor, plays an important role in lymphomagenesis. It binds Stat recognition-like DNA elements and is required for affinity maturation of mature B cells in germinal centers and Th1/Th2 differentiation, a process that critically depends on BCL6-mediated transcriptional repression of p53. BCL6 is a pharmacological target for eradication of leukemia-initiating cells in chronic myeloid leukemia (CML). |
BCL6 Antibody |
6985-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: BCL6 Antibody: BCL6 was first identified as a proto-oncogene in diffuse large B cell lymphoma. BCL6, a transcriptional repressor, plays an important role in lymphomagenesis. It binds Stat recognition-like DNA elements and is required for affinity maturation of mature B cells in germinal centers and Th1/Th2 differentiation, a process that critically depends on BCL6-mediated transcriptional repression of p53. BCL6 is a pharmacological target for eradication of leukemia-initiating cells in chronic myeloid leukemia (CML). |
Bcl6 antibody |
70R-34469 |
Fitzgerald |
100 ug |
EUR 392.4 |
Description: Rabbit polyclonal Bcl6 antibody |
BCL6 Antibody |
1-CSB-PA005439 |
Cusabio |
|
|
|
Description: A polyclonal antibody against BCL6. Recognizes BCL6 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, ELISA;WB:1/500-1/2000.ELISA:1/20000 |
BCL6 Antibody |
1-CSB-PA171912 |
Cusabio |
|
|
|
Description: A polyclonal antibody against BCL6. Recognizes BCL6 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:1000-1:2000, WB:1:200-1:1000, IHC:1:25-1:100 |
BCL6 Antibody |
1-CSB-PA040220 |
Cusabio |
|
|
|
Description: A polyclonal antibody against BCL6. Recognizes BCL6 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC:1/100-1/300.ELISA:1/10000 |
BCL6 Antibody |
1-CSB-PA040221 |
Cusabio |
|
|
|
Description: A polyclonal antibody against BCL6. Recognizes BCL6 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.ELISA:1/40000 |
BCL6 Antibody |
1-CSB-PA908823 |
Cusabio |
|
|
|
Description: A polyclonal antibody against BCL6. Recognizes BCL6 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:25-1:100 |
BCL6 Antibody |
F50351-0.08ML |
NSJ Bioreagents |
0.08 ml |
EUR 140.25 |
Description: BCL6 is a zinc finger transcription factor and contains an N-terminal POZ domain. This protein acts as a sequence-specific repressor of transcription, and has been shown to modulate the transcription of START-dependent IL-4 responses of B cells. This protein can interact with a variety of POZ-containing proteins that function as transcription corepressors. |
BCL6 Antibody |
F50351-0.4ML |
NSJ Bioreagents |
0.4 ml |
EUR 322.15 |
Description: BCL6 is a zinc finger transcription factor and contains an N-terminal POZ domain. This protein acts as a sequence-specific repressor of transcription, and has been shown to modulate the transcription of START-dependent IL-4 responses of B cells. This protein can interact with a variety of POZ-containing proteins that function as transcription corepressors. |
BCL6 Antibody |
F40298-0.08ML |
NSJ Bioreagents |
0.08 ml |
EUR 140.25 |
Description: The protein encoded by this gene is a zinc finger transcription factor and contains an N-terminal POZ domain. This protein acts as a sequence-specific repressor of transcription, and has been shown to modulate the transcription of START-dependent IL-4 responses of B cells. This protein can interact with a variety of POZ-containing proteins that function as transcription corepressors. This gene is found to be frequently translocated and hypermutated in diffuse large-cell lymphoma (DLCL), and may be involved in the pathogenesis of DLCL. Alternatively spliced transcript variants encoding different protein isoforms have been found for this gene. |
BCL6 Antibody |
F42687-0.08ML |
NSJ Bioreagents |
0.08 ml |
EUR 140.25 |
Description: BCL6 is a transcriptional repressor mainly required for germinal center (GC) formation and antibody affinity maturation which has different mechanisms of action specific to the lineage and biological functions. Forms complexes with different corepressors and histone deacetylases to repress the transcriptional expression of different subsets of target genes. Represses its target genes by binding directly to the DNA sequence 5'-TTCCTAGAA-3' (BCL6-binding site) or indirectly by repressing the transcriptional activity of transcription factors. In GC B-cells, represses genes that function in differentiation, inflammation, apoptosis and cell cycle control, also autoregulates its transcriptional expression and up-regulates, indirectly, the expression of some genes important for GC reactions, such as AICDA, through the repression of microRNAs expression, like miR155. An important function is to allow GC B-cells to proliferate very rapidly in response to T-cell dependent antigens and tolerate the physiological DNA breaks required for immunglobulin class switch recombination and somatic hypermutation without inducing a p53/TP53-dependent apoptotic response. In follicular helper CD4+ T-cells (T(FH) cells), promotes the expression of T(FH)-related genes but inhibits the differentiation of T(H)1, T(H)2 and T(H)17 cells. Also required for the establishment and maintenance of immunological memory for both T- and B-cells. Suppresses macrophage proliferation through competition with STAT5 for STAT-binding motifs binding on certain target genes, such as CCL2 and CCND2. In response to genotoxic stress, controls cell cycle arrest in GC B-cells in both p53/TP53-dependedent and -independent manners. Besides, also controls neurogenesis through the alteration of the composition of NOTCH-dependent transcriptional complexes at selective NOTCH targets, such as HES5, including the recruitment of the deacetylase SIRT1 and resulting in an epigenetic silencing leading to neuronal differentiation. [UniProt] |
BCL6 Antibody |
F42687-0.4ML |
NSJ Bioreagents |
0.4 ml |
EUR 322.15 |
Description: BCL6 is a transcriptional repressor mainly required for germinal center (GC) formation and antibody affinity maturation which has different mechanisms of action specific to the lineage and biological functions. Forms complexes with different corepressors and histone deacetylases to repress the transcriptional expression of different subsets of target genes. Represses its target genes by binding directly to the DNA sequence 5'-TTCCTAGAA-3' (BCL6-binding site) or indirectly by repressing the transcriptional activity of transcription factors. In GC B-cells, represses genes that function in differentiation, inflammation, apoptosis and cell cycle control, also autoregulates its transcriptional expression and up-regulates, indirectly, the expression of some genes important for GC reactions, such as AICDA, through the repression of microRNAs expression, like miR155. An important function is to allow GC B-cells to proliferate very rapidly in response to T-cell dependent antigens and tolerate the physiological DNA breaks required for immunglobulin class switch recombination and somatic hypermutation without inducing a p53/TP53-dependent apoptotic response. In follicular helper CD4+ T-cells (T(FH) cells), promotes the expression of T(FH)-related genes but inhibits the differentiation of T(H)1, T(H)2 and T(H)17 cells. Also required for the establishment and maintenance of immunological memory for both T- and B-cells. Suppresses macrophage proliferation through competition with STAT5 for STAT-binding motifs binding on certain target genes, such as CCL2 and CCND2. In response to genotoxic stress, controls cell cycle arrest in GC B-cells in both p53/TP53-dependedent and -independent manners. Besides, also controls neurogenesis through the alteration of the composition of NOTCH-dependent transcriptional complexes at selective NOTCH targets, such as HES5, including the recruitment of the deacetylase SIRT1 and resulting in an epigenetic silencing leading to neuronal differentiation. [UniProt] |
Bcl6 Antibody |
RQ4637 |
NSJ Bioreagents |
100ug |
EUR 356.15 |
Description: B-cell lymphoma 6 protein is a protein that in human is encoded by the BCL6 gene. Like BCL2, BCL3, BCL5, BCL7A, BCL9 and BCL10, it has clinical significance in lymphoma. The protein encoded by this gene is an evolutionarily conserved zinc finger transcription factor and contains an N-terminal POZ/BTB domain. This protein acts as a sequence-specific repressor of transcription and has been shown to modulate the STAT-dependent Interleukin 4 (IL-4) responses of B cells. This protein can interact with several corepressor complexes to inhibit transcription. This gene is found to be frequently translocated and hypermutated in diffuse large B cell lymphoma (DLBCL) and contributes to the pathogenesis of DLBCL. An exon 7 skipping splice variant encodes a shorter form of the protein which lacks the first two zinc fingers of the DNA binding domain. |
Bcl6 Antibody |
V3457-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V3457-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V3457SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V3495-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V3495-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V3495SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V3496-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: First, in the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. Second, Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. Third, Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V3496-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: First, in the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. Second, Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. Third, Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V3496SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: First, in the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. Second, Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. Third, Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V3712-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V3712-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V3712SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V3805-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V3805-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V3805SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V7340-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: First, in the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. Second, Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. Third, Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V7340-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: First, in the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. Second, Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. Third, Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V7340IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 349.3 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: First, in the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. Second, Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. Third, Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V7340SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: First, in the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. Second, Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. Third, Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V7350-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Bcl6 is a transcriptional repressor mainly required for germinal center (GC) formation and antibody affinity maturation which has different mechanisms of action specific to the lineage and biological functions. Forms complexes with different corepressors and histone deacetylases to repress the transcriptional expression of different subsets of target genes. Represses its target genes by binding directly to the DNA sequence 5'-TTCCTAGAA-3' (BCL6-binding site) or indirectly by repressing the transcriptional activity of transcription factors. In GC B-cells, represses genes that function in differentiation, inflammation, apoptosis and cell cycle control, also autoregulates its transcriptional expression and up-regulates, indirectly, the expression of some genes important for GC reactions, such as AICDA, through the repression of microRNAs expression, like miR155. [UniProt] |
Bcl6 Antibody |
V7350-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: Bcl6 is a transcriptional repressor mainly required for germinal center (GC) formation and antibody affinity maturation which has different mechanisms of action specific to the lineage and biological functions. Forms complexes with different corepressors and histone deacetylases to repress the transcriptional expression of different subsets of target genes. Represses its target genes by binding directly to the DNA sequence 5'-TTCCTAGAA-3' (BCL6-binding site) or indirectly by repressing the transcriptional activity of transcription factors. In GC B-cells, represses genes that function in differentiation, inflammation, apoptosis and cell cycle control, also autoregulates its transcriptional expression and up-regulates, indirectly, the expression of some genes important for GC reactions, such as AICDA, through the repression of microRNAs expression, like miR155. [UniProt] |
Bcl6 Antibody |
V7350IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 349.3 |
Description: Bcl6 is a transcriptional repressor mainly required for germinal center (GC) formation and antibody affinity maturation which has different mechanisms of action specific to the lineage and biological functions. Forms complexes with different corepressors and histone deacetylases to repress the transcriptional expression of different subsets of target genes. Represses its target genes by binding directly to the DNA sequence 5'-TTCCTAGAA-3' (BCL6-binding site) or indirectly by repressing the transcriptional activity of transcription factors. In GC B-cells, represses genes that function in differentiation, inflammation, apoptosis and cell cycle control, also autoregulates its transcriptional expression and up-regulates, indirectly, the expression of some genes important for GC reactions, such as AICDA, through the repression of microRNAs expression, like miR155. [UniProt] |
Bcl6 Antibody |
V7350SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Bcl6 is a transcriptional repressor mainly required for germinal center (GC) formation and antibody affinity maturation which has different mechanisms of action specific to the lineage and biological functions. Forms complexes with different corepressors and histone deacetylases to repress the transcriptional expression of different subsets of target genes. Represses its target genes by binding directly to the DNA sequence 5'-TTCCTAGAA-3' (BCL6-binding site) or indirectly by repressing the transcriptional activity of transcription factors. In GC B-cells, represses genes that function in differentiation, inflammation, apoptosis and cell cycle control, also autoregulates its transcriptional expression and up-regulates, indirectly, the expression of some genes important for GC reactions, such as AICDA, through the repression of microRNAs expression, like miR155. [UniProt] |
Bcl6 Antibody |
V2840-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Recognizes a protein of 95kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V2840-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: Recognizes a protein of 95kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V2840IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 349.3 |
Description: Recognizes a protein of 95kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V2840SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Recognizes a protein of 95kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V8063-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: The specificity of this monoclonal antibody to its intended target was validated by HuProtTM Array, containing more than 19,000, full-length human proteins. Recognizes a protein of 95kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large ('LH') cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V8063-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: The specificity of this monoclonal antibody to its intended target was validated by HuProtTM Array, containing more than 19,000, full-length human proteins. Recognizes a protein of 95kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large ('LH') cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V8063SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: The specificity of this monoclonal antibody to its intended target was validated by HuProtTM Array, containing more than 19,000, full-length human proteins. Recognizes a protein of 95kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large ('LH') cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V8064-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Recognizes a protein of 95kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large ('LH') cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V8064-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: Recognizes a protein of 95kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large ('LH') cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Bcl6 Antibody |
V8064SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Recognizes a protein of 95kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large ('LH') cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma. |
Mouse Peptide YY (PYY) Peptide (OVA) |
20-abx651199 |
Abbexa |
-
EUR 427.20
-
EUR 260.40
-
EUR 1178.40
-
EUR 526.80
-
EUR 343.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Peptide YY (PYY) Peptide (OVA) |
20-abx651848 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2064.00
-
EUR 828.00
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Rat Galanin Like Peptide (GALP) Peptide |
20-abx650475 |
Abbexa |
-
EUR 777.60
-
EUR 326.40
-
EUR 2364.00
-
EUR 927.60
-
EUR 560.40
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Peptide 810 |
H-2586.0001 |
Bachem |
1.0mg |
EUR 529.2 |
Description: Sum Formula: C59H91N13O17S; CAS# [156371-22-1] |
Peptide 810 |
H-2586.0005 |
Bachem |
5.0mg |
EUR 2010 |
Description: Sum Formula: C59H91N13O17S; CAS# [156371-22-1] |
Formyl Peptide Receptor-like 2 Peptide |
43-293P |
ProSci |
0.1 mg |
EUR 405.6 |
Dog Brain Natriuretic Peptide (BNP) Peptide |
20-abx065598 |
Abbexa |
-
EUR 1062.00
-
EUR 393.60
-
EUR 3400.80
-
EUR 1262.40
-
EUR 727.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Pig Brain Natriuretic Peptide (BNP) Peptide |
20-abx065601 |
Abbexa |
-
EUR 994.80
-
EUR 376.80
-
EUR 3199.20
-
EUR 1195.20
-
EUR 693.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Rat Brain Natriuretic Peptide (BNP) Peptide |
20-abx652109 |
Abbexa |
-
EUR 910.80
-
EUR 360.00
-
EUR 2865.60
-
EUR 1095.60
-
EUR 644.40
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Canine C Peptide(C Peptide) ELISA Kit |
ECA0028 |
FN Test |
96T |
EUR 681.12 |
|
Description: Method of detection: Coated with Antigen, Competitive ELISA;Reacts with: Canine;Sensitivity: 0.469 ng/ml |
Rat Atrial Natriuretic Peptide (ANP) Peptide |
20-abx065483 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2064.00
-
EUR 828.00
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Rat Atrial Natriuretic Peptide (ANP) Peptide |
20-abx065484 |
Abbexa |
-
EUR 777.60
-
EUR 326.40
-
EUR 2331.60
-
EUR 910.80
-
EUR 560.40
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Now it is clear that IAPP can also have a pathological role in AD, reducing cognitive function. IAPP harms blood-brain barriers, directly interacting and co-deposits with Aβ, promoting dementia associated with diabetes. IAPP can cause metabolic dysfunction in the brain, which leads to other diabetes advertisements. Thus, here we discuss the IAPP associations with diabetes, Aβ and dementia, in the context of what we specify “brain diabetes phenotype”. The hypothesis such approach helps establish a conceptual framework for IAPP-based drugs in the future against AD.